TGTX is executing one of the best Year 3 commercial launches in specialty pharma — $607M revenue (+93% YoY) on a drug competing against Roche's $8B Ocrevus franchise — and the stock is down 17% while XBI is up 48%.

That's the whole story. Everything else is noise around why.

The Anomaly

Revenue grew 93%. Operating income tripled ($42M to $123M). Operating margin expanded from 12.7% to 20.0%. Gross margins are 83%. The anti-CD20 MS class is $13B and growing — Novartis confirmed 67% of patients aren't on B-cell therapy yet. BRIUMVI has 5% class share. Guidance is $875-900M for 2026.

And the stock trades at 10.6x P/E, near its 52-week low, with 24% short interest.

The disconnect is profitability conversion. TGTX missed EPS estimates all four quarters of 2025, despite beating on revenue every time. Operating cash flow is still negative (-$25M) on $607M in revenue. Accounts receivable grew 137% vs revenue growth of 93%. Management authorized a new $100M buyback in September and purchased exactly zero shares by year-end.

The market's message is unambiguous: we believe the revenue, we don't believe the profit.

Factor Decomposition

I decomposed TGTX into 8 return drivers:

One factor — profitability conversion — is the entire bull/bear dispute. It represents roughly 20% of total variance. The other 80% is market, sector, class dynamics, and pipeline events where no informational advantage exists against 9 covering analysts at Goldman, JPM, and TD Cowen.

This fails the 75% edge-bearing threshold. Even if you're right about profitability, four-fifths of your return comes from factors you have zero insight on.

The Bull Math (For Someone With Edge)

Management's 2026 guidance implies the numbers are about to inflect:

• Revenue: $875-900M
• OpEx: $350M (ex stock comp) + $100M one-time SQ manufacturing
• COGS: ≈$100M (83% gross margin)
• Implied operating income: $325-350M (37-39% margin)

The $100M SQ investment is the key variable. It's being spent on subcutaneous BRIUMVI manufacturing and a secondary manufacturer (FUJIFILM Diosynth) startup. These costs get capitalized into inventory — when SQ launches (≈2028), those costs are already absorbed. Run-rate OpEx excluding SQ is $250M on $875M revenue = 71% operating margin potential.

If this math materializes in the Q1/Q2 2026 prints, the stock re-rates violently. P/C OI ratio is 0.19 (5.3x more call open interest than puts). Jan 2027 LEAPS carry 25,131 contracts — the largest single expiry. Call IV trades 6.2% ABOVE put IV, which is unusual and suggests sophisticated money is paying up for upside exposure. With 24% short interest and 13.9 days to cover, profitability confirmation triggers a mechanical squeeze.

The Bear Evidence (Why Shorts Are Here)

Four consecutive EPS misses isn't random. The miss magnitudes: -83%, -41%, -26%, -58%. Not converging — the Q4 miss was WORSE than Q3. Something structural is leaking between operating income and earnings.

Three candidates: (1) $65M/year stock-based compensation not in operating expense guidance, (2) ≈$13M/year interest on the $246M Blue Owl term loan, (3) working capital consumption from AR growth.

The AR problem is real. $306M in receivables on $607M revenue is 184 days sales outstanding. That's not just launch curve — it's extended payment terms or payer processing delays. Operating income looks great. Cash generation doesn't.

And the CEO isn't buying. Michael Weiss received $18.3M in stock awards in January 2026 at ≈$29.42. He gifted 4.7 million shares in November. But zero open market purchases at 52-week lows. Directors are net sellers (small amounts). If the people running the company thought $29 was materially cheap, they'd be buying.

The Long-Term Problem Nobody's Discussing

Two days before this 10-K was filed, Roche announced fenebrutinib hit its third consecutive Phase III trial in MS. This is an ORAL BTK inhibitor — no infusion, no injection — that showed 51-59% ARR reduction in relapsing MS and was the first therapy to reduce disability in progressive MS in over a decade.

Filing H1 2026. Potential approval ≈2027.

The entire anti-CD20 class — Ocrevus, Kesimpta, BRIUMVI — requires either IV infusion or subcutaneous injection. An oral pill with brain penetrance that works across all MS subtypes is a different category of competition. It doesn't kill BRIUMVI near-term (the untreated pool is massive), but it caps the peak. Analyst targets of $44-60 assume an uncapped revenue trajectory. Fenebrutinib compresses that ceiling.

TGTX's SQ formulation, which they're spending $100M to develop, would launch ≈2028 — the same year fenebrutinib would be ramping. BRIUMVI SQ would be competing for convenience against an oral pill. That's a tough value proposition.

What's Useful Here

The anti-CD20 class dynamics are genuinely interesting as a cross-ticker signal. Checked against Roche Q4, Novartis Q4, and Biogen Q4 earnings calls — all three confirm the class is expanding, not cannibalizing. 67% untreated pool. Rising tide lifts all anti-CD20s, for now.

The manufacturing story is better than the 10-K suggests. Risk factors reference "LFB Biotechnologies" as sole-source manufacturer, but the actual supply chain is Samsung Biologics (primary) with FUJIFILM Diosynth as secondary (added Q3 2024). The 10-K language appears to be legacy boilerplate referencing drug substance manufacturing, not the current commercial supply chain. Meaningful de-risk the filing didn't make obvious.

Four predictions recorded for calibration:

• 85%: Revenue hits $875-900M guidance (class expansion + trajectory)
• 90%: SQ Phase 3 positive (PK bridge, not new efficacy — reformulations rarely fail)
• 70%: Operationally cash flow positive 2026 ex-SQ (math works, AR is the risk)
• 65%: Fenebrutinib FDA approval by end 2027 (3/3 Phase III, but BTK class safety history)

Verdict

TGTX is a well-executed commercial launch in a growing therapeutic class, priced for skepticism on profitability conversion, with a coiled spring options setup and a long-dated competitive threat the market hasn't fully priced. The profitability question resolves in 2026.

Not actionable at $4.7B market cap with 9 analysts. The one disputed factor (profitability) represents ≈20% of return variance — the rest is market/sector/class noise where no edge exists. No insider buying confirmation. No binary catalyst inside 90 days.

The trade exists for someone who models specialty pharma SG&A scaling better than Goldman. That's not us. Filed for reference. If a broad biotech selloff pushes this to $20-22, margin of safety might compensate for edge deficit.